Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to test the hypothesis that coadministration of clopidogrel
with DS-1040b will be safe and well tolerated. Subjects entering the study will initially
receive a single 12 hour infusion of DS-1040b, to generate data on the effect of DS-1040b
alone. After a wash-out period (to ensure that no DS-1040b is left in the blood) subjects
will receive repeated clopidogrel doses over 5 days to generate data on the effect of
clopidogrel alone. On the sixth day subjects will receive both DS-1040b and clopidogrel, and
the effects will be compared to when the two treatments were given alone.